Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor α production of monocytes

Shock

Volumn 15, Issue 2, 2001, Pages 101-105

  Aosasa, Suefumi ^a   Ono, Satoshi ^a   Mochizuki, Hidetaka ^a   Tsujimoto, Hironori ^a   Ueno, Chikara ^a   Matsumoto, Atsushi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Cytokine; Gabexate mesilate; IL 10; Monocyte; NF B; Protease inhibitor; TNF ; Ulinastatin

Indexed keywords

GABEXATE; GLYCOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEIN KINASE C; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN;

ARTICLE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MONOCYTE; SIGNAL TRANSDUCTION;

CELLS, CULTURED; GABEXATE; GLYCOPROTEINS; HUMANS; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MONOCYTES; NF-KAPPA B; PROTEASE INHIBITORS; PROTEIN KINASE C; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035259695     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200115020-00004     Document Type: Article

References (35)

1. Davies MG, Hagen PO: Systemic inflammatory response syndrome. Br J Surg 84:920-935, 1997.
2. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24:163-172, 1996.
3. Tani T, Aoki H, Yoshioka T, Lin KJ, Kodama M: Treatment of septic shock with a protease inhibitor in a canine model: a prospective, randomized, controlled trial. Crit Care Med 21:925-930, 1993.
4. Taenaka N, Shimada Y, Hirata T, Nishijima MK, Takezawa J, Yoshiya I, Kambayashi J: Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med 11:735-738, 1983.
5. Ono S, Aosasa S, Mochizuki H: Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg 177:78-82, 1999.
6. Remick DG: Applied molecular biology of sepsis. J Crit Care 10:198-212, 1995.
7. Tamaki S, Wada H, Hiyoyama K, Shimura M, Minamikawa K, Wakita Y, Nakase T, Ohiwa M, Kaneko T, Iwasaki E, et al.: Treatment of disseminated intravascular coagulation with gabexate mesilate. Clin Therap 15: 1076-1084, 1993.
8. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V: Gabexate for the prevention of pancreatic damage related to endoscopie retrograde cholangiopancreatography: gabexate in digestive endoscopy -Italian Group. N Engl J Med 335:919-923, 1996.
9. Tani T, Abe H, Endo Y, Hanasawa K, Kodama M: Effects of a urinary trypsin inhibitor on acute circulatory insufficiency after surgical operation. Am J Surg 175:142-145, 1998.
10. Aosasa S, Ono S, Seki S, Takayama E, Tadakuma T, Hiraide H, Mochizuki H: Inhibitory effect of protease inhibitor on endothelial cell activation. J Surg Res 80:182-187, 1998.
11. Murakami K, Okajima K, Uchiba M, Okabe H, Takatsuki K: Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit Care Med 24:1047-1053, 1996.
12. Taoka Y, Okajima K, Uchiba M, Murakami K, Kushimoto S, Johno M, Naruo M, Okabe H, Takatsuki K: Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats. Crit Care Med 25:874-879, 1997.
13. Aibiki M, Cook JA: Ulinastatin, a human trypsin inhibitor, inhibits endotoxin-induced thromboxane B2 production in human monocytes. Crit Care Med 25:430-434, 1997.
14. Haveman JW, Muller Kobold AC, Tervaert JW, van den Berg AP, Tulleken JE, Kallenberg CG, The TH: The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth J Med 55:132-141, 1999.
15. Darville T, Giroir B, Jacobs R: The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy. Infection 21:279-290, 1993.
16. Fong Y, Moldawer LL, Shires GT, Lowry SF: The biologic characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 170:363-378, 1990.
17. Aggarwal BB, Eessalu TE, Hass PE: Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 318:665-667, 1985.
18. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV: Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171:35-47, 1990.
19. Lenardo MJ, Baltimore D: NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 58:227-229, 1989.
20. Schutze S, Machleidt T, Kronke M: Mechanisms of tumor necrosis factor action. Semin Oncol 19:16-24, 1992.
21. Shapira L, Takashiba S, Champagne C, Amar S, Van Dyke TE: Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-alpha and IL-1 beta production by human monocytes. J Immunol 153:1818-1824, 1994.
22. West MA, LeMieur T, Clair L, Bellingham J, Rodriguez, JL: Protein kinase C regulates macrophage tumor necrosis factor secretion: direct protein kinase C activation restores tumor necrosis factor production in cndotoxin tolerance. Surgery 122:204-211, 1997.
23. Dekker LV, Parker PJ: Protein kinase C: a question of specificity. Trends Biochem Sci 19:73-77, 1994.
24. Nishizuka Y: Protein kinase C and lipid signaling for sustained cellular responses. Faseb J 9:484-496, 1995.
25. Siebenlist U, Franzoso O, Brown K: Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10:405-455, 1994.
26. Finco TS, Baldwin AS: Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Immunity 3:263-272, 1995.
27. Baldwin AS, Jr.: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14:649-683, 1996.
28. Poli V, Cortese R: Interleukin 6 induces a liver-specific nuclear protein that binds to the promoter of acute-phase genes. Proc Natl Acad Sci USA 86:8202-8206, 1989.
29. Lo CJ, Fu M, Kim B: Macrophage TNF mRNA expression is modulated by protease inhibitors. J Surg Res 69:408-412, 1997.
30. Chen CC, Rosenbloom CL, Anderson DC, Manning AM: Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation. J Immunol 155:3538-3545, 1995.
31. Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin 10. J Exp Med 174:1549-1555, 1991.
32. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 11:165-190, 1993.
33. Wang P, Wu P, Siegel MI, Egan RW, Billah MM: Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270:9558-9563, 1995.
34. Shames BD, Selzman CH, Meldrum DR, Pulido EJ, Barton HA, Meng X, Harken AH, McIntyre RC, Jr.: Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes. Shock 10:389-394, 1998.
35. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS, Jr.: Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:31868-31874, 1999.